Lizza Hendriks retweeted
🫵 Want to master the latest breakthroughs in advanced #NSCLC targeted therapies ? Here’s everything you need, straight from the leading experts …@LancetRespirMed @HendriksLizza @MartinReck2
0
20
68
2,940
Thanks for inviting me to speak at this fantastic conference. With teamwork we can really advance the treatment for these patients
Brilliant keynote from @HendriksLizza - ‘Breaking Barriers, Redefining Brain Metastases Treatment Concepts” at #snoasco2026
-identifying pts at high risk
-optimizing tx and sequencing
-access- trials, molecular testing, drugs, knowledge
-multiD teamwork and collaborations
0
2
13
1,060
Lizza Hendriks retweeted
Local ablative therapy has been increasingly appealing as a therapeutic strategy in advanced NSCLC, but patient selection remains a challenge. In @JCO_ASCO, a description of "metastatic trajectories" akin to PSA velocity acknowledges that heterogeneity.
ascopubs.org/doi/10.1200/JC…
ascopubs.org/doi/10.1200/JC…
1
15
43
2,707
Lizza Hendriks retweeted
Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO
3
13
36
5,510
Lizza Hendriks retweeted
1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.
On behalf of the EORTC–ESTRO OligoCare consortium.
5
107
265
35,716
Lizza Hendriks retweeted
@piet_ost @LancetOncology @EORTC @ESTRO_RT @HendriksLizza @Mat_Guc @Icro_Meattini @FelixEhretMD @Hoda_Aty @Silke_Gillessen @finn_corinne @drdavidpalma Important @LancetOncology consensus endorses endpoints that permit repeat MDT without classifying it as failure - exactly what @rweichselbaum and I argued: radiation unmasks dormant disease, making standard progression a flawed benchmark.
jamanetwork.com/journals/jamao…
jamanetwork.com/journals/jamao…
2
8
25
1,769
Lizza Hendriks retweeted
Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC
0
15
53
2,235
Lizza Hendriks retweeted
Countdown to the TSJCI International Cancer Conference ‘ Transforming Cancer Research and Care’ April 14-15. Join us to hear Prof Lizza Hendricks present the research on precision oncology for NSCLC.
1
5
13
427
Lizza Hendriks retweeted
A heart breaking but inspiring journey - from a world leader in cancer research on his own personal diagnosis. Worth a listen for every single person who treats cancer.
And worth a call to double down on clinical trials & research, as well as efforts to identify non-responders.
And worth a call to double down on clinical trials & research, as well as efforts to identify non-responders.
At #TTLC26, @DRCamidge shared powerful insights shaped by both clinical expertise and personal experience living with #lungcancer.
His presentation reminds us why continued innovation in #lungcancer research is essential to improving patient outcomes every day. oU
0
2
13
1,235
Lizza Hendriks retweeted
2025: Summary of Ttx for NSCLC in 3 slides
➕: IO is SoC in early stage
➖: multiple « me too » agents but cost of drugs is ⬆️ and access is ⬇️ worldwide
✏️: optimal Ttx duration with IO or TT
✏️: access to TT for rare 🧬altertions
✏️: role of ADCs?
We need more Academic trials!
➕: IO is SoC in early stage
➖: multiple « me too » agents but cost of drugs is ⬆️ and access is ⬇️ worldwide
✏️: optimal Ttx duration with IO or TT
✏️: access to TT for rare 🧬altertions
✏️: role of ADCs?
We need more Academic trials!
0
63
166
11,011
Lizza Hendriks retweeted
🚀 Can SBRT alone be used to treat oligometastatic cancer—allowing selected patients to defer systemic therapy?
Our meta-analysis, now published in @JAMANetworkOpen, evaluates systemic therapy–free survival after SBRT without upfront systemic therapy.
Our meta-analysis, now published in @JAMANetworkOpen, evaluates systemic therapy–free survival after SBRT without upfront systemic therapy.
5
14
43
2,271
Lizza Hendriks retweeted
After a superb ESMO Asia meeting #ESMOAsia2025 , it's time to start the ESMO Lung Preceptorship with our Asian colleagues... a comprehensive program and exchanges that promise to be rich...@myESMO @peters_solange @HendriksLizza
0
5
21
1,228
Lizza Hendriks retweeted
Today we have had our Autumn 🍁EORTC LCG meeting. A multidisciplinary group discussing new trials in the treatment landscape of thoracic malignancies. New ideas💡for trials and discussions in a friendly ambience. Thanks all for the feedback! @EORTC
0
8
25
2,931
Lizza Hendriks retweeted
Data from the Dutch cancer Registry on survival in patients with NSCLC and leptomeningeal metastases @LungCaJournal from @HendriksLizza group. OS with best supportive care 1.3m, with chemo +/- IO ~8m, with targeted therapy 20.5m. Importance of testing.
lungcancerjournal.info/article/S0169-…
lungcancerjournal.info/article/S0169-…
1
17
37
3,612
Including editorial to put these very relevant findings into context, thanks to all great insights from my co-authors! @myESMO annalsofoncology.org/article/S0923-…
🆕article in press: #ESMO25 editorial article “Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC” @HendriksLizza annalsofoncology.org/article/S0923-…
2
1
11
1,395
Lizza Hendriks retweeted
📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC @Nicmmzh126
bit.ly/3J5dlqk
bit.ly/3J5dlqk
0
6
14
1,415
RT @JordiRemon: UNREST sIII NSCLC is a new hot topic
-PACIFIC remains SoC
Efforts to improve but:
-Intensification IO consol ❌
-IO with CRT…
-PACIFIC remains SoC
Efforts to improve but:
-Intensification IO consol ❌
-IO with CRT…
0
21
0
Lizza Hendriks retweeted
New online! Unresectable stage III non-small-cell lung cancer: state of the art and challenges nature.com/articles/s4157…
0
1
4
1,208
Lizza Hendriks retweeted
How is EGFR+ NSCLC managed in the Netherlands? 🇳🇱
In this episode of #LungCancerConsidered in Dutch, @HendriksLizza moderates a discussion with Dr. Marthe Paats and Dr. Gerrina Ruiter on current treatment strategies.
🎧 bit.ly/DutchEGFRNSCLC
#NSCLC #EGFR
In this episode of #LungCancerConsidered in Dutch, @HendriksLizza moderates a discussion with Dr. Marthe Paats and Dr. Gerrina Ruiter on current treatment strategies.
🎧 bit.ly/DutchEGFRNSCLC
#NSCLC #EGFR
0
2
11
1,083
Lizza Hendriks retweeted
Pleased to welcome Dr. @HendriksLizza (NL) to the Lung Cancer session at #EIOC2025
Pulmonologist at Maastricht UMC, she leads clinical lung cancer research & trials in NSCLC, SCLC, targeted therapy & immunotherapy.
🔗 Register: cancercongress.ae/registration/
#OncologyCare #LungCancer
Pulmonologist at Maastricht UMC, she leads clinical lung cancer research & trials in NSCLC, SCLC, targeted therapy & immunotherapy.
🔗 Register: cancercongress.ae/registration/
#OncologyCare #LungCancer
0
1
3
682